East India Pharmaceutical Works Limited
₹79▲0.00%(0.00)
About the company
East India Pharmaceutical Works Limited (EIPWL) is one of India’s oldest pharmaceutical companies, with a legacy dating back to 1936. Headquartered in Kolkata, West Bengal, the company is engaged in the manufacturing and marketing of pharmaceutical formulations and bulk drugs. It operates in the healthcare and pharmaceutical sector and remains an unlisted public company.
Over the decades, EIPWL has developed a diversified portfolio across therapeutic and healthcare categories, including analgesics, antibiotics, hematinics, vitamins, gastrointestinal medicines and Ayurvedic formulations. Its well-known brands include Pyrigesic, Locula, Tonoferon, Vitazyme and Enteroquinol, among others.
The company has manufacturing operations in Sarsuna, Kolkata and Durgapur, West Bengal. Its facilities support pharmaceutical formulation manufacturing as well as API production, with the company highlighting WHO-GMP-compliant manufacturing capabilities.
Business & Product Portfolio
East India Pharmaceutical Works operates across:
Pharmaceutical formulations
Bulk drugs / APIs
Tablets and capsules
Dry syrups and liquid formulations
Ointments and topical products
Vitamins and hematinics
Analgesic and antipyretic medicines
Gastrointestinal medicines
Antibiotic and anti-infective formulations
Ayurvedic and healthcare products
The company has historically invested in research and development and has built a nationwide distribution presence for its products.
Manufacturing & R&D
EIPWL's manufacturing infrastructure includes a formulation facility at Sarsuna and an API/synthetic drugs facility at Durgapur. Its operations cover manufacturing, quality control, research and development and pharmaceutical packaging.
The company states that its focus is on developing quality and affordable medicines while continuing to strengthen its R&D and healthcare capabilities.
Financial Performance
According to the financial data presented on the UnlistedZone reference page, revenue increased from approximately ₹234 Cr in FY23 to ₹250 Cr in FY24 and ₹272 Cr in FY25. However, profitability was comparatively weaker, with PAT moving from ₹3.8 Cr in FY24 to approximately ₹2 Cr in FY25.
The FY25 annual report describes the company as an established pharmaceutical manufacturer with WHO-GMP-compliant facilities and a portfolio spanning multiple therapeutic categories.
This combination of revenue growth and relatively modest profitability makes margin performance, operating efficiency and sustainable earnings growth important factors for investors to monitor.
Shareholding & Corporate Information
As of FY25, the reference data shows approximately 25.87% promoter holding and 74.13% holding under others. The company has an authorised share capital of ₹10 Cr and paid-up capital of approximately ₹6.67 Cr.
Company: East India Pharmaceutical Works Limited
Incorporated: 27 April 1936
CIN: U24231WB1936PLC008598
ISIN: INE254X01017
Registered Office: Kolkata, West Bengal
Face Value: ₹10 per share
Listing Status: Unlisted
Paid-up Capital: ~₹6.67 Cr
Promoter Holding: 25.87% as of FY25
East India Pharmaceutical Works Unlisted Shares
Since East India Pharmaceutical Works Limited is not listed on NSE or BSE, its shares do not have a continuously traded exchange price. Indicative prices available through unlisted-share platforms can vary depending on transaction demand, available supply, valuation expectations and market conditions.
The historical reference page from UnlistedZone displays ₹79 as an indicative price dated 3 November 2021, while other current data sources show different indicative levels. Therefore, any price displayed on an unlisted-share page should be treated as indicative and subject to confirmation, rather than as a guaranteed executable price.
Why Investors Track East India Pharmaceutical Works
Some factors that may attract investor interest include:
Nearly nine decades of operating history
Established pharmaceutical manufacturing capabilities
Diversified product portfolio
Presence across formulations and APIs
Recognised legacy brands
WHO-GMP-compliant manufacturing capabilities
Established distribution network
Exposure to India's long-term healthcare and pharmaceutical demand
At the same time, investors should evaluate profitability, working capital requirements, debt, valuation, liquidity and the absence of an exchange-listed market before considering an investment.
Key Risks to Consider
Investment in unlisted shares carries additional risks compared with listed securities. For East India Pharmaceutical Works, investors should particularly evaluate:
Limited liquidity in unlisted shares
Indicative price volatility
Pharmaceutical regulatory and compliance requirements
Competition within the pharmaceutical industry
Raw-material and manufacturing costs
Margin pressure
Working-capital requirements
Execution and business-performance risks
Limited public-market price discovery
Uncertainty regarding any future IPO or listing
There is no guarantee that East India Pharmaceutical Works will list its shares on a stock exchange or that an investor will realise a profit.
Explore East India Pharmaceutical Works Limited Unlisted Shares with Dhankirti and conduct your own due diligence before making an investment decision.
Fundamentals
Valuation
Registry
| Metric | Value |
|---|---|
| PAN number | AAACE5779P |
| ISIN number | INE254X01017 |
Figures in cr ·
Financials
| P&L Statement | 2025Latest | 2024 | 2023 |
|---|---|---|---|
| Revenue | 272 | 250 | 234 |
| EBITDA | 13 | 12.4 | 10 |
| OPM | 4.78 | 4.96 | 4.27 |
| PBT | 4 | 4.5 | 2.4 |
| PAT | 2 | 3.8 | 1.7 |
| EPS | 3 | 5.7 | 2.55 |
Shareholding Pattern
| Holder | Percentage |
|---|---|
| Promoters | 25.87% |
| Others | 74.13% |
Leadership
| Name | Role | Experience | |
|---|---|---|---|
| D. Duttagupta | Managing Director | 30+ yrs experience | — |
| Mrs. S. Mukherjee | Director | 25+ yrs experience | — |
| S. Ray | CFO | 30+ yrs experience | — |
Frequently asked questions
Common questions on East India Pharmaceutical Works Limited—tap a row to read the answer.
Q.1What are East India Pharmaceutical Works Limited unlisted shares?
East India Pharmaceutical Works Limited unlisted shares are equity shares of the company that are not traded on any recognized stock exchange. These shares are bought and sold through private transactions in the unlisted market, offering investors an opportunity to invest in the company before any potential public listing.
Q.2How can I buy East India Pharmaceutical Works Limited unlisted shares?
You can purchase East India Pharmaceutical Works Limited unlisted shares through registered brokers or intermediaries that specialize in unlisted share transactions. Once the buyer and seller agree on the price and quantity, the necessary documentation is completed, and the shares are transferred to the buyer's Demat account.
Q.3Is it legal to invest in East India Pharmaceutical Works Limited unlisted shares?
Yes. Buying and selling East India Pharmaceutical Works Limited unlisted shares is legal in India when the transaction follows applicable laws and regulatory guidelines. Investors should ensure that the shares are transferred through valid procedures and credited to their Demat account.
Q.4Why do investors consider East India Pharmaceutical Works Limited unlisted shares?
Many investors consider East India Pharmaceutical Works Limited unlisted shares because of the company's long operating history, established presence in the pharmaceutical industry, and potential for future business growth. However, investment decisions should always be based on careful analysis of the company's financial performance, valuation, and long-term prospects.
Q.5What should I evaluate before investing in East India Pharmaceutical Works Limited unlisted shares?
Before investing, review the company's financial statements, revenue and profit trends, product portfolio, management team, manufacturing capabilities, debt position, competitive strengths, and future growth strategy. Assessing these factors can help you determine whether the investment aligns with your financial goals.
Q.6Can I sell East India Pharmaceutical Works Limited unlisted shares whenever I want?
Yes, provided there is a willing buyer. Since unlisted shares are traded privately rather than on stock exchanges, the time required to complete the transaction depends on buyer availability, mutually agreed pricing, and the completion of transfer formalities.
Q.7What is East India Pharmaceutical Works Limited
East India Pharmaceutical Works Limited is an Indian pharmaceutical company established in 1936. It manufactures and markets pharmaceutical formulations and bulk drugs and operates as an unlisted public company.
Q.8Is East India Pharmaceutical Works Limited listed?
No. East India Pharmaceutical Works Limited is currently an unlisted public company and its shares are not traded on NSE or BSE.
Q.9Where is East India Pharmaceutical Works headquartered?
The registered office of the company is in Kolkata, West Bengal.
Q.10What are some popular brands of East India Pharmaceutical Works?
Some brands associated with the company include Pyrigesic, Locula, Tonoferon, Vitazyme and Enteroquinol.
Q.11Where are the company's manufacturing facilities located?
The company has manufacturing operations in Sarsuna, Kolkata and Durgapur, West Bengal.
Q.12Why is the unlisted-share price different from the stock-market price?
Because East India Pharmaceutical Works is not listed on NSE or BSE, there is no regular exchange-traded market price. Private-market indicative levels can differ based on availability, demand, valuation and transaction terms.
Unlisted Trending shares
High-demand unlisted opportunities currently available for trade.
MARKET INSIGHTS & UPDATES
Read the latest updates, investment ideas, and market insights designed to help investors better understand unlisted and pre-IPO opportunities.

Polymatech Accelerates Global Expansion: Strengthening Its Semiconductor and Electronics Manufacturing Business
Polymatech Electronics is expanding its global semiconductor operations, diversifying into finished products, power electronics and PCB manufacturing while strengthening its international presence across key markets.

MSE Announces Currency Derivatives Mock Trading: Latest MSE News and Updates
Metropolitan Stock Exchange (MSE) announces a Currency Derivatives mock trading session. Explore the trading schedule, member instructions, official circular and latest MSE developments.

Unlisted Shares in India 2026: Latest Market Updates, Prices & Pre-IPO Opportunities
Explore the latest unlisted shares market trends in India for November 2026. Learn about pre-IPO shares, recent IPO developments, indicative share prices, valuation changes and investment risks. Discover what investors should consider before buying or selling unlisted shares.

Sunday PropTech Acquires 89-Room Kolkata Hotel: What It Means for Sunday PropTech Unlisted Shares
Sunday PropTech, the PRISM-backed hospitality ownership company also known as OYO Assets, has acquired an 89-room hotel in Kolkata’s Rajarhat, marking its entry into eastern India. This guide explains the deal, how Sunday PropTech’s ownership model works, what it means for Sunday PropTech unlisted shares and which risks to weigh.

Sun Drops Energia Plans ₹50 Crore Preferential Issue: EGM on November 26, 2026
Sun Drops Energia, part of KP Group, is asking shareholders to approve a ₹50 crore preferential issue at ₹407 per share. Here is the price logic, use of funds, and what it means for shareholding.

Porter Elevates Mohit Rathi to Chief Marketing Officer
Porter has promoted Mohit Rathi to Chief Marketing Officer. Here’s a look at his journey from growth marketing to the C-suite and Porter’s recent leadership changes.
